Highlights Shanxi Zhendong Pharmaceutical Co.,Ltd

Equities

300158

CNE100000YR9

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 19/06/2024 BST			5-day change	1st Jan Change
3.9 ^CNY	-0.76%		-4.41%	-42.22%

05-20	Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Board Appointments	CI
05-06	Tranche Update on Shanxi Zhendong Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on February 6, 2024.	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Tranche Update on Shanxi Zhendong Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on February 6, 2024.	05-06	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd's Equity Buyback announced on February 6, 2024, has closed with 22,174,904 shares, representing 2.16% for CNY 102.76 million.	04-29	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-22	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	04-22	CI
Tranche Update on Shanxi Zhendong Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on February 6, 2024.	04-03	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd agreed to acquire additional 53.985% stake in Guangdong Longchuangji Pharmaceutical Co., Ltd. from Guangdong Qiangji Pharmaceutical Co., Ltd.	03-07	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd announces an Equity Buyback for CNY 200 million worth of its shares.	02-06	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd authorizes a Buyback Plan.	02-05	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	22/10/23	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	30/08/23	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	24/04/23	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	24/04/23	CI
FountainVest Capital Partners Fund IV, L.P., a fund managed by Fountain Vest Capital Partners GP4 Ltd. completed the aquistion of Beijing Zhendong Langdi Pharmaceutical Co., Ltd. from Shanxi Zhendong Pharmaceutical Co.,Ltd.	27/10/22	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	25/10/22	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	21/08/22	CI
Zhongtai Asset Management Plan No. 45 Single Asset Management Plan, managed by Zhongtai Securities Asset Management Co.,Ltd. completed the acquisition of a 5% stake in Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE : 300158) from Shanxi Zhendong Health Industry Group Co., Ltd.	14/07/22	CI
Zhongtai Asset Management Plan No. 45 Single Asset Management Plan, managed by Zhongtai Securities Asset Management Co.,Ltd. signed a share transfer agreement to acquire a 5% stake in Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE : 300158) from Shanxi Zhendong Health Industry Group Co., Ltd. for approximately CNY 340 million.	19/06/22	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on 09 May 2022	26/04/22	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Approves 2021 Profit Distribution Plan	25/04/22	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	21/04/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Shanxi Zhendong Pharmaceutical Co.,Ltd

Equities

300158

CNE100000YR9

Highlights

Filters